Carvedilol May Help Childhood Cancer Survivors Avoid Later Heart Failure
12 Jan 2024
Drug ApprovalPhase 3
FRIDAY, Jan. 12, 2024 -- Childhood cancer survivors are at increased risk of developing heart failure later in life, due to the chemotherapy that was used to save their lives.
But an already approved drug might help reduce that risk, according to a new report published Jan. 9 in The Lancet Oncology journal.
A blood vessel-relaxing medication called carvedilol is safe for childhood cancer survivors to take and shows promise in reducing the effects of heart injury caused by chemo.
“The growing number of childhood cancer survivors makes the development of early interventions imperative,” said researcher Dr. Saro Armenian, chair of pediatrics at City of Hope Children’s Cancer Center in Los Angeles.
The trial focused on a devastating long-term side effect from a class of chemo called anthracyclines -- increased risk of heart failure, in which the heart becomes too weak to pump enough blood to meet the body’s needs.
The chemo’s damage takes effect gradually over time, as the heart muscle thins and the heart’s chambers enlarge.
Unfortunately, the downward cascade is irreversible after heart function starts to decline, making it urgent that means are found to protect childhood cancer survivors before trouble starts.
Carvedilol is a beta blocker used to treat high blood pressure and heart failure. The U.S. Food and Drug Administration approved the drug in 1995, and it is now available as a generic.
The trial involved 182 childhood cancer survivors across the United States and Canada who took relatively low doses of carvedilol or a placebo for two years.
The clinical trial did not achieve its goal of decreasing the thinning of the heart muscle and enlargement of the chambers, results show.
However, there were significant improvements in the wall stress of the heart’s left lower chamber, or ventricle, researchers said. This is an earlier biomarker of worsening heart health.
Additionally, more patients on placebo developed clinically significant decline in heart function than those on carvedilol -- six versus two, Armenian said.
“The greatest benefit was seen in participants who were very long-term survivors, as well as in those who were highly adherent to the study medication,” Armenian said.
Overall, the trial “sets the stage for a Phase 3 clinical trial that may demonstrate a significant benefit for certain patients who are at an especially high risk of irreversible heart function decline after completion of cancer therapy,” Armenian said.
Sources
City of Hope, news release, Jan. 9, 2024
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Posted January 2024
More news resources
FDA Medwatch Drug Alerts
Daily MedNews
News for Health Professionals
New Drug Approvals
New Drug Applications
Drug Shortages
Clinical Trial Results
Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Drugs
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.